Trade

with

Medivation Inc
(NASDAQ: MDVN)
AdChoices
101.87
+2.47
+2.48%
After Hours :
101.89
+0.02
+0.02%

Open

99.41

Previous Close

99.40

Volume (Avg)

653.76k (1.15M)

Day's Range

99.28-102.16

52Wk Range

54.37-103.88

Market Cap.

7.63B

Dividend Rate ( Yield )

-

Beta

0.76

Shares Outstanding

76.79M

P/E Ratio (EPS)

322.58 (0.30)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 272.94M

    • Net Income

    • -42.61M

    • Market Cap.

    • 7.63B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 6.05

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.76

    • Forward P/E

    • 32.26

    • Price/Sales

    • 19.76

    • Price/Book Value

    • 53.19

    • Price/Cash flow

    • 212.77

      • EBITDA

      • -18.80M

      • Return on Capital %

      • 5.64

      • Return on Equity %

      • 23.13

      • Return on Assets %

      • 5.64

      • Book Value/Share

      • 1.87

      • Shares Outstanding

      • 76.79M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 116.57

        • Credit Rating

        • -

        • Analysts

        • 7

        • EPS Estimate

        • 2.44

        • Cashflow Estimate

        • 0.53

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 111.10

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 85.05

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • 6.46

            • 39.38

            • Net Profit Margin

            • 6.05

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -45.80

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -47.20

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 1.62

              • 0.76

              • Current Ratio

              • 4.76

              • 2.92

              • Quick Ratio

              • 4.47

              • 2.35

              • Interest Coverage

              • 2.21

              • 38.02

              • Leverage Ratio

              • 3.37

              • 2.21

              • Book Value/Share

              • 1.87

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 322.58

                • 243.90

                • P/E Ratio 5-Year High

                • 341.53

                • 634.30

                • P/E Ratio 5-Year Low

                • 13.86

                • 124.82

                • Price/Sales Ratio

                • 19.76

                • 9.29

                • Price/Book Value

                • 53.19

                • 8.39

                • Price/Cash Flow Ratio

                • 212.77

                • 49.75

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 23.13

                    (-323.50)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 5.64

                    (-15.70)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 13.54

                    (-299.50)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 54.76k

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.93

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -22.24M
                  Operating Margin
                  -8.15
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  212.77
                  Ownership

                  Institutional Ownership

                  98.87%

                  Top 10 Institutions

                  45.85%

                  Mutual Fund Ownership

                  57.76%

                  Float

                  84.42%

                  5% / Insider Ownership

                  2.69%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    2,433,685

                  • 0.00

                  • 3.17

                  • Franklin Biotechnology Discovery

                  •  

                    2,116,100

                  • 84.62

                  • 2.77

                  • Bb Biotech AG

                  •  

                    1,429,706

                  • -4.67

                  • 1.86

                  • Vanguard Small Cap Index

                  •  

                    1,267,152

                  • 0.01

                  • 1.65

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,184,552

                  • 0.19

                  • 1.54

                  • iShares Nasdaq Biotechnology

                  •  

                    997,056

                  • -0.24

                  • 1.29

                  • Wells Fargo Advantage Growth Fund

                  •  

                    977,803

                  • 11.39

                  • 1.27

                  • Vanguard Small Cap Growth Index Fund

                  •  

                    856,506

                  • -1.97

                  • 1.12

                  • Fidelity® Independence Fund

                  •  

                    842,100

                  • 0.00

                  • 1.10

                  • Franklin US Opportunities

                  •  

                    773,000

                  • 74.61

                  • 1.01

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    6,315,798

                  • -19.81%

                  • 8.23

                  • Franklin Advisers, Inc.

                  •  

                    4,615,299

                  • +4.31%

                  • 6.02

                  • Janus Capital Management LLC

                  •  

                    4,497,073

                  • +1.35%

                  • 5.86

                  • Vanguard Group, Inc.

                  •  

                    4,392,324

                  • -3.55%

                  • 5.73

                  • Adage Capital Partners Gp LLC

                  •  

                    3,972,060

                  • -14.80%

                  • 5.18

                  • Blair William & Co

                  •  

                    2,458,698

                  • +0.38%

                  • 3.21

                  • Orbimed Advisors, LLC

                  •  

                    2,446,600

                  • -10.19%

                  • 3.19

                  • Knoll Capital Management LP

                  •  

                    2,279,519

                  • 0.00%

                  • 2.97

                  • Pyramis Global Advisors, LLC

                  •  

                    2,158,233

                  • -4.23%

                  • 2.81

                  • Wellington Management Company, LLP

                  •  

                    2,030,132

                  • -10.39%

                  • 2.65

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Mid Growth

                  Medivation, Inc was formed in Delaware in October 1995. The Company is a biopharmaceutical company engaged in the rapid development of novel small molecule drugs to treat diseases for which there are limited treatment options. Togeth...moreer with its collaboration partner Astellas Pharma Inc., or Astellas, the Company is developing XTANDI "enzalutamide" capsules. Together with Astellas, it is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. Based on the positive results of the AFFIRM trial, the Company has exercised its right under its collaboration agreement with Astellas to co-promote XTANDI in the...more U.S., should it receive marketing approval. Their subsidiaries are Medivation Prostate Therapeutics, Inc., or MPT, Medivation Neurology, Inc., or MNI, Medivation Technologies, Inc., or MTI, Medivation Field Solutions, Inc., or MFSI, and Medivation Services, Inc., or MSI. MPT holds the intellectual property rights covering XTANDI. MNI holds the intellectual property rights covering dimebon, which was in development for Alzheimer’s disease and Huntington disease under its former collaboration with Pfizer. MTI holds the intellectual property rights covering its early-stage technologies. MFSI provides commercialization services to the Company, and MSI provides research and development services. It has received “Fast Track” designation from the U.S. Food and Drug Administration for the post-docetaxel indication. The Company is conducting this program in collaboration with Astellas. The Company is subject to extensive regulation by the Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.lessless

                  Key People

                  Dr. David T. Hung,M.D.

                  CEO/Co-Founder/Director/President

                  Kim D. Blickenstaff

                  Director/Chairman of the Board

                  Rick Bierly

                  Chief Accounting Officer/CFO

                  C. Patrick Machado

                  Director

                  Kathryn E. Falberg

                  Director

                  • Medivation Inc

                  • 36th Floor, 525 Market Street

                  • San Francisco, CA 94105

                  • USA.Map

                  • Phone: +1 415 543-3470

                  • Fax: +1 415 543-3411

                  • medivation.net

                  Incorporated

                  1995

                  Employees

                  433

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: